Sebastian Unizony

Clinical Interests:

• ANCA-associated vasculitis
• Aortitis
• Behcet's syndrome
• Cryoglobulinemia
• Dermatomyositis
• Giant cell arteritis
• Lupus
• Rheumatoid arthritis

Medical Education

• MD, Universidad Nacional de La Plata
• Residency, Hospital Carlos Durand
• Residency, St. Luke's Roosevelt Hospital Center
• Fellowship, Massachusetts General Hospital

American Board Certifications

• Rheumatology, American Board of Internal Medicine

Publications

• Unizony S, Lu N, Tomasson G et al. Temporal trends of venous thromboembolism risk before and after diagnosis of giant cell arteritis. Arthritis Rheumatol. 2017
• Miyabe C, Miyabe Y, Strle K, Kim ND, Stone JH, Luster AD and Unizony S. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis. 2016
• Unizony S, Villarreal M, Miloslavsky EM et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016
• Unizony S, Kim ND, Hoang MP. Case Records of the Mass General Hospital. Case 7-2015: A 25-year-old man with oral ulcers, rash, and odynophagia. N Engl J Med. 2015
• Unizony S, Menendez ME, Rastalsky N, et al. Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency. Rheumatology (Oxford). 2015
• Unizony S, Lim N, Phippard DJ, et al. Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2015
• Miloslavsky EM, Stone JH, Unizony S. Challenging mimickers of primary systemic vasculitis. Rheum Dis Clin North Am. 2015
• Unizony S, Dasgupta B, Fisheleva E, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013